Serum Sema3A Is in a Weak Positive Association With Bone Formation Marker Osteocalcin But Not Related to Bone Mineral Densities in Postmenopausal Women
Context:The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.Objective:The aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women...
Saved in:
Published in | The journal of clinical endocrinology and metabolism Vol. 99; no. 12; pp. E2504 - E2509 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Oxford University Press
01.12.2014
Copyright by The Endocrine Society |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Context:The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.Objective:The aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women.Design, Setting, and Participants:This was a cross-sectional study involving 1012 pre- and postmenopausal women.Main Outcome Measures:Fasting serum Sema3A, osteocalcin (Ocn), and cross-linked C-telopeptide of type 1 collagen were measured. Dual-energy X-ray absorptiometry was performed to determine the BMDs at the lumbar spine and femoral neck. History of osteoporotic fractures was reported by the participants.Results:In postmenopausal women (n = 860), a significant positive association between Sema3A and Ocn levels was demonstrated (r = 0.077, P = 0.025) when age was adjusted. The serum Ocn level was significantly higher in the fourth quartile of serum Sema3A as compared with the first quartile (21.09 ± 0.56 ng/mL vs 19.45 ± 0.44 ng/mL, P = .018). Serum Sema3A concentrations were similar in subjects with normal BMD, osteopenia or osteoporosis, and those with and without osteoporotic fractures. Multivariate stepwise regression analysis revealed that cross-linked C-telopeptide of type 1 collagen, body mass index, creatinine, Sema3A, L1–4 BMDs, and age were determinants of Ocn (adjusted R2 for the model = 0.532, P < .001) .Conclusions:The positive correlation between Sema3A and bone formation marker Ocn revealed in this human study partly supports the recently findings in mice studies. However, the general effects of Sema3A on bone metabolism are weak and not clear as evidenced by lack of association between this parameter and BMDs and osteoporotic fractures. |
---|---|
AbstractList | Context:The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.Objective:The aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women.Design, Setting, and Participants:This was a cross-sectional study involving 1012 pre- and postmenopausal women.Main Outcome Measures:Fasting serum Sema3A, osteocalcin (Ocn), and cross-linked C-telopeptide of type 1 collagen were measured. Dual-energy X-ray absorptiometry was performed to determine the BMDs at the lumbar spine and femoral neck. History of osteoporotic fractures was reported by the participants.Results:In postmenopausal women (n = 860), a significant positive association between Sema3A and Ocn levels was demonstrated (r = 0.077, P = 0.025) when age was adjusted. The serum Ocn level was significantly higher in the fourth quartile of serum Sema3A as compared with the first quartile (21.09 ± 0.56 ng/mL vs 19.45 ± 0.44 ng/mL, P = .018). Serum Sema3A concentrations were similar in subjects with normal BMD, osteopenia or osteoporosis, and those with and without osteoporotic fractures. Multivariate stepwise regression analysis revealed that cross-linked C-telopeptide of type 1 collagen, body mass index, creatinine, Sema3A, L1–4 BMDs, and age were determinants of Ocn (adjusted R2 for the model = 0.532, P < .001) .Conclusions:The positive correlation between Sema3A and bone formation marker Ocn revealed in this human study partly supports the recently findings in mice studies. However, the general effects of Sema3A on bone metabolism are weak and not clear as evidenced by lack of association between this parameter and BMDs and osteoporotic fractures. CONTEXT:The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described. OBJECTIVE:The aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women. DESIGN, SETTING, AND PARTICIPANTS:This was a cross-sectional study involving 1012 pre- and postmenopausal women. MAIN OUTCOME MEASURES:Fasting serum Sema3A, osteocalcin (Ocn), and cross-linked C-telopeptide of type 1 collagen were measured. Dual-energy X-ray absorptiometry was performed to determine the BMDs at the lumbar spine and femoral neck. History of osteoporotic fractures was reported by the participants. RESULTS:In postmenopausal women (n = 860), a significant positive association between Sema3A and Ocn levels was demonstrated (r = 0.077, P = 0.025) when age was adjusted. The serum Ocn level was significantly higher in the fourth quartile of serum Sema3A as compared with the first quartile (21.09 ± 0.56 ng/mL vs 19.45 ± 0.44 ng/mL, P = .018). Serum Sema3A concentrations were similar in subjects with normal BMD, osteopenia or osteoporosis, and those with and without osteoporotic fractures. Multivariate stepwise regression analysis revealed that cross-linked C-telopeptide of type 1 collagen, body mass index, creatinine, Sema3A, L1–4 BMDs, and age were determinants of Ocn (adjusted R for the model = 0.532, P < .001) . CONCLUSIONS:The positive correlation between Sema3A and bone formation marker Ocn revealed in this human study partly supports the recently findings in mice studies. However, the general effects of Sema3A on bone metabolism are weak and not clear as evidenced by lack of association between this parameter and BMDs and osteoporotic fractures. The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described. The aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women. This was a cross-sectional study involving 1012 pre- and postmenopausal women. Fasting serum Sema3A, osteocalcin (Ocn), and cross-linked C-telopeptide of type 1 collagen were measured. Dual-energy X-ray absorptiometry was performed to determine the BMDs at the lumbar spine and femoral neck. History of osteoporotic fractures was reported by the participants. In postmenopausal women (n = 860), a significant positive association between Sema3A and Ocn levels was demonstrated (r = 0.077, P = 0.025) when age was adjusted. The serum Ocn level was significantly higher in the fourth quartile of serum Sema3A as compared with the first quartile (21.09 ± 0.56 ng/mL vs 19.45 ± 0.44 ng/mL, P = .018). Serum Sema3A concentrations were similar in subjects with normal BMD, osteopenia or osteoporosis, and those with and without osteoporotic fractures. Multivariate stepwise regression analysis revealed that cross-linked C-telopeptide of type 1 collagen, body mass index, creatinine, Sema3A, L1-4 BMDs, and age were determinants of Ocn (adjusted R(2) for the model = 0.532, P < .001) . The positive correlation between Sema3A and bone formation marker Ocn revealed in this human study partly supports the recently findings in mice studies. However, the general effects of Sema3A on bone metabolism are weak and not clear as evidenced by lack of association between this parameter and BMDs and osteoporotic fractures. The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.CONTEXTThe chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.The aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women.OBJECTIVEThe aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women.This was a cross-sectional study involving 1012 pre- and postmenopausal women.DESIGN, SETTING, AND PARTICIPANTSThis was a cross-sectional study involving 1012 pre- and postmenopausal women.Fasting serum Sema3A, osteocalcin (Ocn), and cross-linked C-telopeptide of type 1 collagen were measured. Dual-energy X-ray absorptiometry was performed to determine the BMDs at the lumbar spine and femoral neck. History of osteoporotic fractures was reported by the participants.MAIN OUTCOME MEASURESFasting serum Sema3A, osteocalcin (Ocn), and cross-linked C-telopeptide of type 1 collagen were measured. Dual-energy X-ray absorptiometry was performed to determine the BMDs at the lumbar spine and femoral neck. History of osteoporotic fractures was reported by the participants.In postmenopausal women (n = 860), a significant positive association between Sema3A and Ocn levels was demonstrated (r = 0.077, P = 0.025) when age was adjusted. The serum Ocn level was significantly higher in the fourth quartile of serum Sema3A as compared with the first quartile (21.09 ± 0.56 ng/mL vs 19.45 ± 0.44 ng/mL, P = .018). Serum Sema3A concentrations were similar in subjects with normal BMD, osteopenia or osteoporosis, and those with and without osteoporotic fractures. Multivariate stepwise regression analysis revealed that cross-linked C-telopeptide of type 1 collagen, body mass index, creatinine, Sema3A, L1-4 BMDs, and age were determinants of Ocn (adjusted R(2) for the model = 0.532, P < .001) .RESULTSIn postmenopausal women (n = 860), a significant positive association between Sema3A and Ocn levels was demonstrated (r = 0.077, P = 0.025) when age was adjusted. The serum Ocn level was significantly higher in the fourth quartile of serum Sema3A as compared with the first quartile (21.09 ± 0.56 ng/mL vs 19.45 ± 0.44 ng/mL, P = .018). Serum Sema3A concentrations were similar in subjects with normal BMD, osteopenia or osteoporosis, and those with and without osteoporotic fractures. Multivariate stepwise regression analysis revealed that cross-linked C-telopeptide of type 1 collagen, body mass index, creatinine, Sema3A, L1-4 BMDs, and age were determinants of Ocn (adjusted R(2) for the model = 0.532, P < .001) .The positive correlation between Sema3A and bone formation marker Ocn revealed in this human study partly supports the recently findings in mice studies. However, the general effects of Sema3A on bone metabolism are weak and not clear as evidenced by lack of association between this parameter and BMDs and osteoporotic fractures.CONCLUSIONSThe positive correlation between Sema3A and bone formation marker Ocn revealed in this human study partly supports the recently findings in mice studies. However, the general effects of Sema3A on bone metabolism are weak and not clear as evidenced by lack of association between this parameter and BMDs and osteoporotic fractures. |
Author | Zhao, Hong-yan Sun, Li-hao Lu, Nan Liu, Dong-mei Tao, Bei Xuan, Yan Wang, Wei-qing Liu, Jian-min Zhang, Min-jia Zhao, Lin Ning, Guang |
AuthorAffiliation | Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 |
AuthorAffiliation_xml | – name: Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 |
Author_xml | – sequence: 1 givenname: Dong-mei surname: Liu fullname: Liu, Dong-mei organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 – sequence: 2 givenname: Nan surname: Lu fullname: Lu, Nan organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 – sequence: 3 givenname: Lin surname: Zhao fullname: Zhao, Lin organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 – sequence: 4 givenname: Min-jia surname: Zhang fullname: Zhang, Min-jia organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 – sequence: 5 givenname: Bei surname: Tao fullname: Tao, Bei organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 – sequence: 6 givenname: Yan surname: Xuan fullname: Xuan, Yan organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 – sequence: 7 givenname: Li-hao surname: Sun fullname: Sun, Li-hao organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 – sequence: 8 givenname: Hong-yan surname: Zhao fullname: Zhao, Hong-yan organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 – sequence: 9 givenname: Wei-qing surname: Wang fullname: Wang, Wei-qing organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 – sequence: 10 givenname: Jian-min surname: Liu fullname: Liu, Jian-min email: liujianmin@medmail.com.cn organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 – sequence: 11 givenname: Guang surname: Ning fullname: Ning, Guang email: guangning@medmail.com.cn organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025 |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25050899$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kkFvFCEUx4mpsdvqzbMh8dAenAoMDOW4rVabtNZYzXojLPMmy-7MsALTxk_i15XZaS9NSkLIg9___17e4wDt9b4HhN5SckIZJR_X9oQRygvKefkCzajiopBUyT00I4TRQkn2ex8dxLgmGeOifIX2mSCCnCo1Q_9uIQwdvoXOlHN8GbHrscELMBv83UeX3B3geYzeOpOc7_HCpRU-yxXgCx-66e7ahA0EfBMTeGtamy3OhoS_-YR_QGsS1Dj5SXTtegimxZ-gH81hly8nSh30fmuGmN8WPgev0cvGtBHePJyH6NfF55_nX4urmy-X5_OrwpaqUgVQZjmtSGMkyJpQJeplVZekASmapaCNUYrVVFhpmqWsLQCplCI11LCklaDlITqefLfB_xkgJt25aKFtTQ9-iJpWJWcya1hG3z9B134Ifa5Ol7TivCKMqUy9e6CGZQe13gbXmfBXP7Y8A2wCbPAxBmi0dWnXyBSMazUlepyrXls9zlWPc82iD09Ej77P4HzC732bIMRNO9xD0CswbVppkhev5GkxCijLUZG3GEs7mmR-2D6XYPfPyv9Q8b9Y |
CitedBy_id | crossref_primary_10_1016_j_cmet_2018_12_021 crossref_primary_10_1007_s00018_018_2981_y crossref_primary_10_3389_fendo_2022_1014431 crossref_primary_10_12998_wjcc_v7_i20_3310 crossref_primary_10_1016_j_mce_2015_09_009 crossref_primary_10_1016_j_biopha_2021_111321 crossref_primary_10_1038_nutd_2017_6 crossref_primary_10_2139_ssrn_4162722 crossref_primary_10_1016_j_bone_2018_06_003 crossref_primary_10_1155_2018_2318386 crossref_primary_10_1155_2019_2506463 crossref_primary_10_1007_s00223_025_01350_4 crossref_primary_10_1177_00220345241231777 crossref_primary_10_1016_j_prmcm_2022_100079 |
ContentType | Journal Article |
Copyright | Copyright © 2014 by the Endocrine Society 2014 Copyright © 2014 by The Endocrine Society Copyright © 2014 by the Endocrine Society |
Copyright_xml | – notice: Copyright © 2014 by the Endocrine Society 2014 – notice: Copyright © 2014 by The Endocrine Society – notice: Copyright © 2014 by the Endocrine Society |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM H94 K9. 7X8 |
DOI | 10.1210/jc.2014-1443 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1945-7197 |
EndPage | E2509 |
ExternalDocumentID | 25050899 10_1210_jc_2014_1443 00004678-201412000-00059 10.1210/jc.2014-1443 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -~X .55 .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 4.4 48X 53G 5GY 5RS 5YH 8F7 AABZA AACZT AAIMJ AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL ABBLC ABDFA ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABVGC ABWST ABXVV ACGFO ACGFS ACPRK ACUTJ ACYHN ADBBV ADGKP ADGZP ADHKW ADQBN ADRTK ADVEK AELWJ AEMDU AENEX AENZO AETBJ AEWNT AFCHL AFFZL AFGWE AFOFC AFRAH AFXAL AGINJ AGKRT AGQXC AGUTN AHMBA AHMMS AJEEA ALMA_UNASSIGNED_HOLDINGS APIBT ARIXL ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BEYMZ BSWAC BTRTY C45 CDBKE CS3 D-I DAKXR DIK E3Z EBS EJD EMOBN ENERS F5P FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 HZ~ H~9 KBUDW KOP KQ8 KSI KSN L7B M5~ MHKGH MJL N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G REU ROX ROZ TEORI TJX TLC TR2 TWZ VVN W8F WOQ X7M YBU YFH YHG YOC YSK ZY1 ~02 ~H1 .GJ 3O- 7X7 88E 8FI 8FJ AAJQQ AAKAS AAPGJ AAQQT AAUQX AAWDT AAYJJ ABDPE ABUWG ABXZS ACFRR ACVCV ACZBC ADMTO ADNBA ADZCM AEMQT AEOTA AERZD AFFNX AFFQV AFKRA AFYAG AGMDO AGORE AHGBF AI. AJBYB AJDVS ALXQX APJGH AQDSO AQKUS AVNTJ BENPR BPHCQ BVXVI CCPQU EIHJH FEDTE FYUFA HMCUK HVGLF IAO IHR INH ITC J5H M1P MBLQV N4W NU- OBFPC PHGZM PHGZT PQQKQ PROAC PSQYO TMA UKHRP VH1 WHG X52 ZGI ZXP AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3969-e12c4160fa7e7d0195db6d30fe75fb51fa992d15c7afb7dcee06990dedeb16513 |
ISSN | 0021-972X 1945-7197 |
IngestDate | Fri Jul 11 16:09:11 EDT 2025 Mon Jun 30 12:42:00 EDT 2025 Thu Apr 03 07:10:57 EDT 2025 Tue Jul 01 01:10:32 EDT 2025 Thu Apr 24 23:12:50 EDT 2025 Fri May 16 03:43:26 EDT 2025 Fri Feb 07 10:35:39 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3969-e12c4160fa7e7d0195db6d30fe75fb51fa992d15c7afb7dcee06990dedeb16513 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 25050899 |
PQID | 3164460229 |
PQPubID | 2046206 |
ParticipantIDs | proquest_miscellaneous_1634276992 proquest_journals_3164460229 pubmed_primary_25050899 crossref_citationtrail_10_1210_jc_2014_1443 crossref_primary_10_1210_jc_2014_1443 wolterskluwer_health_00004678-201412000-00059 oup_primary_10_1210_jc_2014-1443 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20141201 2014-December 2014-12-00 2014-Dec |
PublicationDateYYYYMMDD | 2014-12-01 |
PublicationDate_xml | – month: 12 year: 2014 text: 20141201 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Washington |
PublicationTitle | The journal of clinical endocrinology and metabolism |
PublicationTitleAlternate | J Clin Endocrinol Metab |
PublicationYear | 2014 |
Publisher | Oxford University Press Copyright by The Endocrine Society |
Publisher_xml | – name: Oxford University Press – name: Copyright by The Endocrine Society |
SSID | ssj0014453 |
Score | 2.2373157 |
Snippet | Context:The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.Objective:The... CONTEXT:The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described. OBJECTIVE:The... The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described. The aim of the study... The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.CONTEXTThe... |
SourceID | proquest pubmed crossref wolterskluwer oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | E2504 |
SubjectTerms | Absorptiometry, Photon Adult Aged Aged, 80 and over Biochemical markers Biomarkers - blood Body mass index Bone Density - physiology Bone growth Bone turnover Collagen Collagen Type I - blood Creatinine Creatinine - blood Cross-Sectional Studies Dual energy X-ray absorptiometry Female Fractures Humans Metabolism Middle Aged Osteocalcin Osteocalcin - blood Osteogenesis Osteogenesis - physiology Osteopenia Osteoporosis Post-menopause Postmenopause - physiology Semaphorin-3A - blood Semaphorins Spine (lumbar) Young Adult |
Title | Serum Sema3A Is in a Weak Positive Association With Bone Formation Marker Osteocalcin But Not Related to Bone Mineral Densities in Postmenopausal Women |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201412000-00059 https://www.ncbi.nlm.nih.gov/pubmed/25050899 https://www.proquest.com/docview/3164460229 https://www.proquest.com/docview/1634276992 |
Volume | 99 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAIIe4UBjISPFVGuad55LJpA3W8bGJvkePYqN2aTEsiJP4IP4-_wjm2k7qjFZeXKE2dxMn5fG45F0JelWHsiViELBVBxKI4LFmmwFhJp3IaRyoEkYIO_dlRcnASfTyNT0ejn07UUtcWb8T3jXkl_0NVOAZ0xSzZf6DscFE4APtAX9gChWH7VzSGhd4tYbkvOdj1hzqylU--SH6GPXhNUJDz-oEDtJjcAGrlfp-yqHN15OXkMxAbpZqAS7zr2slR3Zo4OdBHQTvVJ83mukI1sKiq0XVY8X7Y7BcLjl_wrtG-96XNLVusYOhUpxgSMWVV1sCwqlUJqKVsAZDnfUlDDBKad0bHr76ypZwPhzsrFhynd239C7_5wWHSbDHnrnPDj64EimxJmnQZOkaYpLojO4gzw8OzKGapb8J-eyZvujD1YA4clr2HRdwc-Y-_s43CBaxjFC5Y-BJnGpn6UlfKdW8eeI1cD8COwRYbHw4_DZ-5osiWSbVPYTMzMK3KPXtNZ1rLw3TMoVvk9rcaIyyaM51g4ahJx3fJHWvf0LcGrPfISFb3yY2ZjeB4QH5ozFKDWXrY0HlFOUXM0h6z1MEsRcxShB8dMEsNZqmDWQqYpYBZajFL29qcZDFLB8zi_dYxSzVmH5KT_b3j9wfMNgdhIsySjEk_EGBMeIqnMi0x7bUskjL0lExjVcS-4lkWlH4sUq6KtARd0EtA8yplCdpJEvvhI7JTwUSeEMrLwONqmvpFrCKheFEoD3aVF8hwKjwxJpP-9efCVs7HBi7nOVrQQKx8IXIkVo7EGpPXw-gLUzFmyzgKlNw2hJkhuz2Zc7tUmzz0wYRJQPXOxuTl8DcIBfzSxytZd00ORlYUpPC8wZg8NvAYboQ2D37rHxO2hpfcJF7n2msAKizDafh95Yk4e_rn-T4jN1eLeJfstJedfA46e1u80Lj_BcKd6gE |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+Sema3A+Is+in+a+Weak+Positive+Association+With+Bone+Formation+Marker+Osteocalcin+But+Not+Related+to+Bone+Mineral+Densities+in+Postmenopausal+Women&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Liu%2C+Dong-mei&rft.au=Lu%2C+Nan&rft.au=Zhao%2C+Lin&rft.au=Zhang%2C+Min-jia&rft.date=2014-12-01&rft.pub=Oxford+University+Press&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=99&rft.issue=12&rft.spage=E2504&rft.epage=E2509&rft_id=info:doi/10.1210%2Fjc.2014-1443&rft.externalDocID=10.1210%2Fjc.2014-1443 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |